抗病毒固有免疫分子TRIM22 C端SPRY结构域对其转录、翻译及亚细胞定位的影响

本文旨在探讨TRIM22 C端SRPY结构域对其转录、翻译及亚细胞定位的影响。以野生型TRIM22真核表达质粒为模板,扩增出C端SPRY结构域缺失的TRIM22基因片段,并将其克隆入真核表达质粒pcDNA3.1。将野生型和突变型TRIM22真核表达载体分别转染高分化人肝癌细胞株HepG2。通过反转录-聚合酶链反应检测其mRNA表达水平,蛋白质免疫印迹法(Western blot)检测其蛋白表达水平,并通过间接免疫荧光法检测其亚细胞内定位。结果成功构建了C端SPRY结构域缺失的TRIM22真核表达质粒。转染HepG2细胞后,TRIM22 SPRY结构域缺失突变体在转录和翻译水平上均与野生型TRIM22无明显差异,但TRIM22 SPRY结构域缺失突变体完全丧失了核定位能力,这为进一步研究SPRY结构域在TRIM22抗病毒过程中所发挥的作用及机制提供了有益的启示。     

人SDCT2蛋白亚细胞定位信号分析

为了确定人高亲和力钠离子依赖性二羧酸共转运蛋白（high-affinity sodium-dependent dicarboxylate co-transporter, SDCT2,NaDC3）在细胞内的定位,构建了SDCT2与增强型绿色荧光蛋白（EGFP）的融合蛋白表达载体,并转染肾小管上皮细胞LLC-PK1,激光共聚焦显微镜观察显示,SDCT2蛋白主要定位于细胞的基底侧膜上.同时将SDCT2-EGFP融合基因mRNA显微注射到爪蟾卵母细胞中表达,可见融合蛋白的绿色荧光仅分布在细胞膜上.为了进一步确定该蛋白质的亚细胞定位信号序列,将SDCT2基因的N端及C端分别缺失,并构建缺失突变体与EGFP的融合蛋白表达载体,将它们转染到LLC-PK1中,观察SDCT2 缺失体在细胞内的分布情况.结果显示,N端缺失的SDCT2蛋白主要位于细胞质中,顶膜和基底侧膜上也有表达;C端缺失的SDCT2蛋白主要位于基底侧膜上,顶膜几乎没有表达,细胞质中表达很少.免疫组化结果也显示,SDCT2只表达于人近端肾小管上皮细胞的基底侧膜.这表明SDCT2蛋白的N端序列对其亚细胞定位是必需的,人SDCT2蛋白的基底膜定位信号位于N端序列中.     

携带小鼠白介素-4截短型突变体基因的5型腺相关病毒载体的构建及外源蛋白的体外表达

目的:制备携带碳端结构域缺失的小鼠白介素-4(Interleukin-4,IL-4)基因突变体的5型重组腺相关病毒(recombinant adeno-associated virus, r AAV)并在细胞水平检测其介导的外源蛋白表达情况。方法:通过分子克隆技术构建携带小鼠IL-4碳端22个氨基酸缺失的突变体的表达质粒pSNAV-mIL-4ΔC22,三质粒共转染法制备重组的5型AAV病毒,体外感染人支气管上皮样细胞系16HBE和BEAS-2B,并通过Western blot和ELISA检测外源蛋白表达。结果:DNA测序表明构建的小鼠IL-4碳端第118位氨基酸位点处截短的突变体基因表达序列正确无误,制备的重组病毒载体r AAV5-mIL-4ΔC22滴度约为3×10~(11)vg/m L。r AAV5-GFP感染16HBE和BEAS-2B细胞后36小时开始可见持续稳定的荧光蛋白表达,重组病毒r AAV5-mIL-4ΔC22感染16HBE和BEAS-2B细胞后外源蛋白在培养上清中呈分泌型表达。结论:本研究成功构建了携带小鼠IL-4碳端结构域缺失型突变体的AAV表达质粒并制备了重组病毒r AAV5-mIL-4ΔC22,该病毒可有效转染16HBE和BEAS-2B细胞并介导外源基因分泌表达截短型小鼠IL-4突变体蛋白。     

067朊病毒蛋白的信号转导作用

近年来朊病毒蛋白(PrPsc)在传染性脑海绵样病变(TSEs)中作用的研究取得较大的进展,但其胞内非病理性同型体蛋白的PrPc的功能依然不清.PrPc是神经元普遍显著表达的糖蛋白,PrPc缺失的小鼠可存活而且发育正常,而表达截去N端PrPc的小鼠在出生后神经元退化.这给人提示PrPc在调节和维持神经元功能方面起重要作用.     

重组小鼠canstatin N端片段对鸡胚新生血管生成的抑制作用(英)

为了研究重组小鼠canstatin N端片段的体内抗血管生成活性, 通过PCR扩增小鼠canstatin N端片段cDNA,定向克隆于原核表达载体pET30a(+)中,构建小鼠canstatin N端片段重组表达载体pET-mCanN, 转化E.coli BL21(DE3), IPTG诱导表达,SDS-聚丙烯酰胺凝胶电泳(SDS-PAGE)和蛋白质印迹检测小鼠canstatin N端片段的表达. 结果表明,IPTG诱导原核表达载体pET-mCanN在大肠杆菌E.coli BL21(DE3)中高效表达, 小鼠canstatin N端片段表达量约占菌体总蛋白量的18%, 小鼠canstatin N端片段主要以包涵体形式存在,包涵体经过洗涤、裂解、Ni-spin column亲合柱层析以及蛋白质复性等步骤纯化后,获得了纯度约为92%的重组小鼠canstatin N端片段. 鸡胚绒毛尿囊膜(chicken embryo choriollantoic membrane,CAM)实验表明,原核表达的小鼠canstatin N端片段能有效地按剂量依赖的方式抑制鸡胚新生血管的形成.     

Cidea和Cidec促进肝脏中脂类的积累

目的:探讨Cidea和Cidec对肝脏中脂滴大小和脂类积累的影响。方法:首先,检测ob/ob肥胖小鼠的脂肪肝中Cidea和Cidec的表达情况。然后,采用腺病毒系统在野生型小鼠肝脏中过表达Cidea和Cidec,以及在ob/ob小鼠肝脏中基因沉默Cidea和Cidec,检测肝脏中脂滴大小和脂积累情况。结果:Cidea和Cidec在脂肪性肝脏中高表达。肝脏细胞中过表达Cidea和Cidec促进大脂滴的形成并能促进小鼠肝脏中的脂积累,且二者有协同作用。在脂肪肝中沉默Cidea和Cidec能缓解脂肪肝的程度,且脂合成基因的下调,线粒体活性增加。Cidea和Cidec的共沉默能进一步降低肝脏中的脂类积累。结论:Cidea和Cidec在促进肝脏的脂积累中起重要作用,并且二者有协同作用。     

EGFP/SDCT1融合蛋白表达、亚细胞定位信号分析、组织分布及电生理功能研究

从正常人肾中克隆低亲和力钠离子依赖二羧酸共转运蛋白 1(sodium-dependent dicarboxylate co-transporter 1, SDCT1, NADC1)全长基因, 并将其和N端及C端缺失突变的SDCT1基因分别插入增强型绿色荧光蛋白基因(EGFP)表达载体中构建EGFP/SDCT1融合蛋白真核表达载体, 然后将它们转染到人肾小管上皮细胞HKC中表达并用激光共聚焦显微镜观察融合蛋白的亚细胞定位情况以确定其定位信号. 双重PCR分析证实融合基因已整合到细胞基因组中, Western blot显示融合基因已在细胞中得到表达. 共聚焦显微镜分析显示正常人SDCT1蛋白主要定位于细胞膜上, 与生物信息学的预测结果一致, 而C端缺失的SDCT1基因转染的细胞, 其绿色荧光位于细胞质, N端缺失基因转染的细胞, 其绿色荧光主要位于细胞膜上. 将体外转录的融合基因mRNA显微注射到爪蟾卵母细胞中表达并用双电极电压钳技术记录细胞跨膜电流, 结果在卵细胞膜上测定出了Na⁺内向电流. 免疫组化结果显示SDCT1主要表达于人近端肾小管上皮细胞的管腔侧, 而在远端肾小管、集合管、肾间质和肾小球中未见SDCT1的表达. 上述研究表明, 正常人SDCT1蛋白定位于近端肾小管上皮细胞的管腔侧膜上, SDCT1蛋白的C端部分对于其合成后的迁移及靶向定位是必需的, 人SDCT1蛋白的细胞膜定位序列可能位于其C端部分.     

丁酸钠至少部分通过NF-Y 依赖的TXNIP 表达诱导人肺癌细胞A549死亡

组蛋白去乙酰化酶（HDACs）抑制剂丁酸钠调节细胞分化、增殖和抑制肿瘤发生。硫氧还蛋白相互作用蛋白( thioredoxin-interacting protein,TXNIP)通过负性调控硫氧还蛋白的活性,调控细胞内的氧化还原平衡,抑制细胞生长。本研究证明,丁酸钠可通过激活依赖于转录因子NF-Y的TXNIP 表达,诱导人非小细胞肺癌细胞A549死亡。MTT法显示,5 mmol/L丁酸钠处理A549 细胞72 h可显著诱导其死亡;流式细胞分析发现,其中大部分细胞以凋亡形式死亡。表达芯片分析表明,在丁酸钠处理的A549 细胞中,TXNIP 的mRNA 水平显著提高30～50倍;实时定量PCR、免疫细胞化学和蛋白质印迹结果进一步证明,丁酸钠可显著上调TXNIP 表达。荧光素酶报告基因分析证明,与对照细胞比较,丁酸钠刺激的细胞内报告酶活性可提高约10 倍,提示丁酸钠可激活TXNIP 启动子的转录活性。TXNIP 启动子删除突变分析显示,删除NF-Y 结合的DNA 序列显著降低丁酸钠对TXNIP 启动子的激活能力, 表明NF-Y转录因子参与丁酸钠介导的TXNIP基因转录激活。为分析TXNIP 在A549 细胞中的定位和部分功能,在A549细胞 中过表达GFP TXNIP 融合蛋白及其截短突变体融合蛋白;结果显示,野生型和保留N 端1-281aa的截短突变体定位在细胞核,而删除N 端1-200aa 时,其定位在细胞核和细胞质,提示N 端1 200aa 可调节该蛋白质的定位。然而,丁酸钠刺激未发现表达的GFP TXNIP在细胞内定位改变。以上结果表明,丁酸钠可通过激活转录因子NF YC 依赖的TXNIP激活,诱导A549 细胞死亡,但不能改变TXNIP蛋白在细胞内的定位。上述结果还提示,TXNIP 的N 端1-200aa 可能在调节TXNIP 的细胞定位中发挥作用。是否丁酸钠刺激TXNIP表达导致的细胞死亡系通过改变细胞氧化压力,以及TXNIP在细胞中定位的详尽调节机制尚待进一步研究证明。     

丁酸钠至少部分通过NF-Y依赖的TXNIP表达诱导人肺癌细胞A549死亡北大核心CSCD

组蛋白去乙酰化酶(HDACs)抑制剂丁酸钠调节细胞分化、增殖和抑制肿瘤发生。硫氧还蛋白相互作用蛋白(thioredoxin-interacting protein,TXNIP)通过负性调控硫氧还蛋白的活性,调控细胞内的氧化还原平衡,抑制细胞生长。本研究证明,丁酸钠可通过激活依赖于转录因子NF-Y的TXNIP表达,诱导人非小细胞肺癌细胞A549死亡。MTT法显示,5 mmol/L丁酸钠处理A549细胞72 h可显著诱导其死亡;流式细胞分析发现,其中大部分细胞以凋亡形式死亡。表达芯片分析表明,在丁酸钠处理的A549细胞中,TXNIP的mRNA水平显著提高30~50倍;实时定量PCR、免疫细胞化学和蛋白质印迹结果进一步证明,丁酸钠可显著上调TXNIP表达。荧光素酶报告基因分析证明,与对照细胞比较,丁酸钠刺激的细胞内报告酶活性可提高约10倍,提示丁酸钠可激活TXNIP启动子的转录活性。TXNIP启动子删除突变分析显示,删除NF-Y结合的DNA序列显著降低丁酸钠对TXNIP启动子的激活能力,表明NF-Y转录因子参与丁酸钠介导的TXNIP基因转录激活。为分析TXNIP在A549细胞中的定位和部分功能,在A549细胞中过表达GFP-TXNIP融合蛋白及其截短突变体融合蛋白;结果显示,野生型和保留N端1-281aa的截短突变体定位在细胞核,而删除N端1-200aa时,其定位在细胞核和细胞质,提示N端1-200aa可调节该蛋白质的定位。然而,丁酸钠刺激未发现表达的GFP-TXNIP在细胞内定位改变。以上结果表明,丁酸钠可通过激活转录因子NF-YC依赖的TXNIP激活,诱导A549细胞死亡,但不能改变TXNIP蛋白在细胞内的定位。上述结果还提示,TXNIP的N端1-200aa可能在调节TXNIP的细胞定位中发挥作用。是否丁酸钠刺激TXNIP表达导致的细胞死亡系通过改变细胞氧化压力,以及TXNIP在细胞中定位的详尽调节机制尚待进一步研究证明。     

关于mGluR在脆性X综合征发病机制中的研究新进展

脆性X综合征为最常见的遗传性智力低下性疾病之一,是由于FMR1基因异常导致其编码的脆性X智力低下蛋白减少或缺失所致.研究发现脆性X综合征尸解病人和FMR1基因敲除小鼠(KO鼠)神经元树突棘发育不成熟,模型小鼠海马区代谢性谷氨酸受体所触发的长时程抑制(LTD)延长,不成熟的树突棘导致突触功能障碍被认为是脑功能异常的基础.最近的研究表明,应用代谢性谷氨酸受体拮抗剂能改善由FMRP缺失所导致的突触和行为缺陷,表明mGluR功能过度激活可能参与了脆性X综合征的发病过程,但具体机制不明.FMRP是一种mRNA结合蛋白,可作为翻译抑制因子负性调节突触后膜mRNA的翻译和表达.因此推测FMRP缺乏和减少可能导致mGluR激发的mRNA翻译增多,参与神经系统发育的蛋白过度表达,而影响树突棘的发育,但具体机制仍不清楚.本文对mGluR和脆性X综合征的研究历史和最新进展进行了讨论.     

Cidea controls lipid droplet fusion and lipid storage in brown and white adipose tissue

Excess lipid storage in adipose tissue results in the development of obesity and other metabolic disorders including diabetes,fatty liver and cardiovascular diseases.The lipid droplet(LD)is an important subcellular organelle responsible for lipid storage.We previously observed that Fsp27,a member of the CIDE family proteins,is localized to LD-contact sites and promotes atypical LD fusion and growth.Cidea,a close homolog of Fsp27,is expressed at high levels in brown adipose tissue.However,the exact role of Cidea in promoting LD fusion and lipid storage in adipose tissue remains unknown.Here,we expressed Cidea in Fsp27-knockdown adipocytes and observed that Cidea has similar activity to Fsp27 in promoting lipid storage and LD fusion and growth.Next,we generated Cidea and Fsp27 double-deficient mice and observed that these animals had drastically reduced adipose tissue mass and a strong lean phenotype.In addition,Cidea/Fsp27 double-deficient mice had improved insulin sensitivity and were intolerant to cold.Furthermore,we observed that the brown and white adipose tissues of Cidea/Fsp27double-deficient mice had significantly reduced lipid storage and contained smaller LDs compared to those of Cidea or Fsp27single deficient mice.Overall,these data reveal an important role of Cidea in controlling lipid droplet fusion,lipid storage in brown and white adipose tissue,and the development of obesity.     

Regulation of Cidea protein stability by the ubiquitin-mediated proteasomal degradation pathway

Cidea, one of three members of the CIDE (cell-death-inducing DNA-fragmentation-factor-45-like effector) family of proteins, is highly enriched in brown adipose tissue, in which it plays a critical role in adaptive thermogenesis and fat accumulation. Cidea-null mice have increased energy expenditure with resistance to high-fat-diet-induced obesity and diabetes. However, little is known as to how the Cidea protein is regulated. In the present study we show that Cidea is a short-lived protein as measured by cycloheximide-based protein chase experiments in different cell lines or in differentiated brown adipocytes. Proteasome inhibitors specifically increased the stability of both transfected and endogenous Cidea protein. Furthermore, Cidea protein was found to be polyubiquitinated when overexpressed in different culture cells as well as in differentiated mature brown adipocytes. Extensive mutational analysis of individual lysine residues revealed that ubiquitinated lysine residues are located in the N-terminal region of Cidea, as alteration of these lysine residues to alanine (N-5KA mutant) renders Cidea much more stable when compared with wild-type or C-terminal lysine-less mutant (C-5KA). Furthermore, K23 (Lys23) within the N-terminus of the Cidea was identified as the major contributor to its polyubiquitination signal and the protein instability. Taken together, the results of our study demonstrated that the ubiquitin-proteasome system confers an important post-translational modification that controls the protein stability of Cidea.     

双硫仑治疗小鼠肥胖的安全性和有效性评价

摘要 目的：观察双硫仑治疗小鼠肥胖的安全性和有效性。方法：取6周龄C57BL/6J雄性小鼠10只,高脂饲料诱导肥胖后,随机分为双硫仑组（双硫仑玉米油溶液,300 mg/(kg?d）和对照组（等量玉米油）,每组5只小鼠。每日灌胃给药1次,连续2周,期间仍给与高脂饲料。监测小鼠食物消耗量和体重。给药结束后取小鼠血清、附睾白色脂肪垫、肩胛间区棕色脂肪和肝脏。白色、棕色脂肪和肝脏进行HE染色,观察细胞形态。电镜下观察棕色脂肪细胞内的脂滴和线粒体。Realtime-qPCR法检测棕色脂肪组织中Ucp1、Fabp4、Prdml6和Cidea的mRNA相对表达量,Western blot法检测Ucp1的蛋白表达量。检测血清中转氨酶ALT和AST含量。取8周龄C57BL/6J雄性小鼠10只,随机分为双硫仑组（双硫仑300 mg/(kg?d）和对照组（等量玉米油）,每日灌胃1次,连续2周。给药结束后进行棕色脂肪和肝脏HE染色并检测血清中ALT和AST含量。取8周龄C57BL/6J雄性小鼠10只,随机分为双硫仑组（双硫仑300 mg/(kg?d）和对照组（等量玉米油）,每日灌胃1次,连续4周,进行肝脏HE染色并检测血清中ALT和AST含量。取孕13.5天的C57BL/6J胚胎小鼠,进行成纤维细胞原代培养,分为双硫仑组（双硫仑5 mg/L）和对照组（等量DMSO）并诱导分化为棕色脂肪细胞。分化8天后进行油红O染色,观察脂滴形成情况,检测Ucp1、Fabp4、Prdml6和Cidea的mRNA相对表达量和Ucp1的蛋白表达量。结果：肥胖小鼠给药过程中,双硫仑组和对照组的进食量及体重变化并无明显差别（P＞0.05）。给药结束后,两组白色脂肪细胞大小无明显差别。双硫仑组小鼠棕色脂肪细胞直径和细胞内脂滴明显增大（P＜0.05）,脂滴数量、线粒体形态及数量无明显差别（P＞0.05）。双硫仑组小鼠棕色脂肪中Cidea和Prdm16的mRNA表达减少（P＜0.05）。正常体重小鼠双硫仑给药2周后棕色脂肪细胞脂滴也增大。细胞实验结果显示,双硫仑组脂滴形成明显减少,Ucp1、Cidea、Prdm16的mRNA表达明显减少（P<0.05）;Ucp1的蛋白表达明显减少（P<0.05）。肥胖与正常小鼠双硫仑给药2周后均出现明显的肝细胞水肿,血清中ALT和AST升高（P<0.05）,正常小鼠给药4周后仍有明显肝细胞水肿,ALT和AST升高（P<0.05）。结论：短期使用双硫仑对饮食诱导的肥胖小鼠无明显减肥作用;双硫仑在体内、外均可抑制小鼠棕色脂肪细胞的分化。短期使用双硫仑可引起肝损害。双硫仑用于减肥治疗的安全性及有效性尚不够理想。     

PPARα does not suppress muscle-associated gene expression in brown adipocytes but does influence expression of factors that fingerprint the brown adipocyte

Brown adipocytes and myocytes develop from a common adipomyocyte precursor. PPARα is a nuclear receptor important for lipid and glucose metabolism. It has been suggested that in brown adipose tissue, PPARα represses the expression of muscle-associated genes, in this way potentially acting to determine cell fate in brown adipocytes. To further understand the possible role of PPARα in these processes, we measured expression of muscle-associated genes in brown adipose tissue and brown adipocytes from PPARα-ablated mice, including structural genes (Mylpf, Tpm2, Myl3 and MyHC), regulatory genes (myogenin, Myf5 and MyoD) and a myomir (miR-206). However, in our hands, the expression of these genes was not influenced by the presence or absence of PPARα, nor by the PPARα activator Wy-14,643. Similarly, the expression of genes common for mature brown adipocyte and myocytes (Tbx15, Meox2) were not affected. However, the brown adipocyte-specific regulatory genes Zic1, Lhx8 and Prdm16 were affected by PPARα. Thus, it would not seem that PPARα represses muscle-associated genes, but PPARα may still play a role in the regulation of the bifurcation of the adipomyocyte precursor into a brown adipocyte or myocyte phenotype.     

HRASLS3 is a PPARgamma-selective target gene that promotes adipocyte differentiation

The prevalence of obesity and its associated metabolic diseases worldwide has focused attention on understanding the mechanisms underlying adipogenesis. The nuclear receptor PPARgamma has emerged as a central regulator of adipose tissue function and formation. Despite the identification of numerous PPARgamma targets involved in a range of processes, from lipid droplet formation to adipokine secretion, information is still lacking on targets downstream of PPARgamma that directly affect fat cell differentiation. Here we identify HRASLS3 as a novel PPARgamma regulated gene with a role in adipogenesis. HRASLS3 expression increases during the differentiation of preadipocyte cell lines and is highly expressed in white and brown adipose tissue in mice. HRASLS3 expression is induced by PPARgamma ligands in preadipocyte cell lines as well in adipose tissue in vivo. We demonstrate that the HRASLS3 promoter contains a functional PPAR response element and is a direct target for regulation by PPARgamma/RXR heterodimers. Finally, we show that overexpression of HRASLS3 augments PPARgamma-driven lipid accumulation and adipogenesis, whereas siRNA-mediated knockdown of HRASLS3 expression decreases differentiation. Together, these results identify HRASLS3 as one of the downstream effectors of PPARgamma action in adipogenesis.     

Identification of the lipid droplet targeting domain of the Cidea protein

Cidea, the cell death-inducing DNA fragmentation factor-α-like effector (CIDE) domain-containing protein, is targeted to lipid droplets in mouse adipocytes, where it inhibits triglyceride hydrolysis and promotes lipid storage. In mice, Cidea may prevent lipolysis by binding and shielding lipid droplets from lipase association. Here we demonstrate that human Cidea localizes with lipid droplets in both adipocyte and nonadipocyte cell lines, and we ascribe specific functions to its protein domains. Expression of full-length Cidea in undifferentiated 3T3-L1 cells or COS-1 cells increases total cellular triglyceride and strikingly alters the morphology of lipid droplets by enhancing their size and reducing their number. Remarkably, both lipid droplet binding and increased triglyceride accumulation are also elicited by expression of only the carboxy-terminal 104 amino acids, indicating this small domain directs lipid droplet targeting and triglyceride shielding. However, unlike the full-length protein, expression of the carboxy-terminus causes clustering of small lipid droplets but not the formation of large droplets, identifying a novel function of the N terminus. Furthermore, human Cidea promotes lipid storage via lipolysis inhibition, as the expression of human Cidea in fully differentiated 3T3-L1 adipocytes causes a significant decrease in basal glycerol release. Taken together, these data indicate that the carboxy-terminal domain of Cidea directs lipid droplet targeting, lipid droplet clustering, and triglyceride accumulation, whereas the amino terminal domain is required for Cidea-mediated development of enlarged lipid droplets.